Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, today announces positive results from a Phase I trial of ZP1848 for the treatment of Crohn’s disease. ZP1848 is a potent and selective GLP-2 agonist discovered by Zealand Pharma that is targeted to offer a novel treatment option for patients with Crohn’s disease due to its regenerative effect on the intestinal surface and enhancement of intestinal function.
The Phase I clinical study was conducted in 60 healthy volunteers and 10 Crohn’s disease patients in remission. ZP1848 was found to be safe and well tolerated. In addition, the pharmacological effects of ZP1848 were demonstrated in the 10 Crohn’s disease patients. This was achieved by studying the biomarker citrulline, which is an indicator of the regeneration of mucosal cells and the well-being of the gut. The results showed that there was a clear positive effect on the levels of citrulline in patients treated with ZP1848, compared to patients treated with placebo. The increase in citrulline levels was significant and indicates that ZP1848 has an effect on enhancing epithelial growth, as well as increasing absorptive area and improving gut function. Zealand Pharma is currently preparing a Phase IIa study including endoscopic examinations in Crohn’s disease patients which the Company believes will commence in 2012.
Crohn’s disease, an inflammatory bowel disease (IBD), most commonly affects the last part of the small intestine (the terminal ileum) and parts of the large intestine. However, the disease is not limited to these areas and can affect any part of the digestive tract. Currently available treatments target the symptomatic inflammation associated with IBD whereas ZP1848 works by enhancing the regeneration and healing of the small intestine lining after an inflammatory episode in the gut.
Commenting on today’s announcement, David Solomon, Chief Executive Officer and President of Zealand Pharma, said: “We are pleased to announce positive Phase I results from this study, which has demonstrated safety and tolerability in healthy volunteers and in Crohn’s disease patients. We are excited that ZP1848 has the potential to provide an alternative treatment paradigm for patients suffering from inflammatory bowel disease.” www.2n2u.com
Betelgeuse really is a big star.
If placed at the center of our Solar System it would extend
to the orbit of Jupiter.
But like all stars except the Sun,
Betelgeuse is so distant it
usually appears as a
single point of light, even in large telescopes.
Still, astronomers using
at infrared wavelengths
can resolve the surface of Betelgeuse and
image of the
The intriguing picture shows two, large, bright, star spots.
potentially represent enormous
convective cells rising
from below the supergiant's surface.
They are bright because they're hotter than the rest
of the surface, but both spots and surface are
cooler than the Sun.
Also known as Alpha Orionis, Betelgeuse is about 600 light-years
You can link to this article on your web site using following code:
We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.